Healthcare Equipment and Supplies
Company Overview of electroCore LLC
electroCore LLC operates as an electroceutical healthcare company that develops non-invasive vagus nerve stimulation (nVNS) therapies for the treatment of multiple conditions in neurology, psychiatry, and gastroenterology conditions. The company focuses on treatment of primary headache such as migraine and cluster headache conditions, along with trials in epilepsy, gastric motility disorders, depression, and anxiety conditions. It offers gammaCore, a vagus nerve stimulator. electroCore LLC was founded in 2005 and is headquartered in Basking Ridge, New Jersey with additional offices in Germany, Italy, Australia, Canada, New Zealand, and the United Kingdom.
150 Allen Road
Basking Ridge, NJ 07920
Founded in 2005
Key Executives for electroCore LLC
Co-Founder, Chief Executive Officer and Director
Co-Founder and Chief Science Officer
Co-Founder, Principal Investor and Director
Vice President of Finance
Compensation as of Fiscal Year 2014.
electroCore LLC Key Developments
electroCore Llc Presents Latest Trail Advances on its gammaCore Therapy
Sep 22 14
electroCore LLC announced that it has presented at international Headache Meeting (EHMTICi) latest trail advances on its electroCore’s gammaCore therapy. Large scale randomized clinical trial of the gammaCore therapy in chronic cluster headache not only significantly reduced the number of cluster headache attacks beyond the best available standard of care, but also that patients experienced a greater reduction in number of attacks the longer they stayed on treatment. Treatment with gammaCore also resulted in meaningful improvements in quality of life and a reduction in the use of traditional rescue medications such as injectable sumatriptan and oxygen. Cluster headache is a condition that affects approximately the same number of people as multiple sclerosis, and is considered by experts to be one of the most painful medical conditions known to medicine. GammaCore’s demonstrated effects represent a significant breakthrough in the care of patients with this debilitating condition. More particularly, the Prevention and Acute Treatment of Chronic Cluster Headache (PREVA) randomized and open label trial data were presented in three poster presentations and at a breakout symposium on Saturday evening, highlighting the following key findings: Patients receiving gammaCore plus standard of care achieved a 43.4% reduction in the number of weekly cluster headache attacks compared with 12.5% (p=0.002) in patients treated with the best available standard of care. Treatment with gammaCore was more effective the longer patients remained on therapy. The quality of life measurements measured by EQ-5-3L VASiii and HIT-6iv were meaningful for those on gammaCore. Patients on gammaCore (in the randomized phase) reduced their use of sub cutaneous sumatriptan and oxygen by >60%. Nearly 64% indicated that they would recommend the use of gammaCore to a family member or friend. 56% of patients found treatment with gammaCore very easy to use. Treatment with gammaCore was safe and can be used in combination with drug treatments. Device related adverse events were primarily mild and transient. gammaCore is a revolutionary non-invasive vagus nerve stimulation (nVNS) therapy developed by electroCore. The patient delivers the therapy by holding the device on the neck over the vagus nerve for 90 seconds (link to picture) which painlessly delivers a proprietary electrical signal that activates specific fibers in the vagus nerve bundle. This stimulates the production of inhibitory transmitters in the central nervous system, and reduces the over expression of the excitatory neurotransmitter glutamate, which has been implicated in a number of headache disorders. The PREVA trial, which is part of the trial program ever carried out in cluster headache, was conducted at ten sites across Europe with 97 patients enrolled. Ninety-three were randomized to participate following the initial baseline data collection. Forty-five of the patients were randomly selected to use gammaCore plus their usual treatment and 48 to the best available standard of care. The baseline data collection period was two-weeks, followed by the four-week randomized phase. All the patients from both arms were asked to continue on active therapy for an additional four-week open label phase. The dosing of the therapy used in the PREVA trial was three, 120-second stimulations, delivered at two time points during each day.
electroCore Presents Full Data on Their Preva Study on Non-Invasive PREVA Nerve Stimulation Therapy for Cluster Headache
Sep 16 14
electroCore will be presenting at the international headache meeting in Copenhagen (EHMTIC) its full data on their PREVA study, a randomized, multi-center trial across several European countries, which showed that preventative use of non-invasive vagus nerve stimulation (nVNS) can substantially reduce the frequency of cluster headache attacks (by 43.4%) versus the control group (the current standard of care, which experienced only a 12% reduction). Three poster presentations will provide full details of the PREVA trial and include: A report on the randomized phase. A report on the open label phase. An analysis of quality of life impact.
electoCore Medical Presents at FT Global Pharmaceuticals and Biotechnology Conference 2014, Nov-18-2014 11:00 AM
Aug 26 14
electoCore Medical Presents at FT Global Pharmaceuticals and Biotechnology Conference 2014, Nov-18-2014 11:00 AM. Venue: Marriott Hotel Grosvenor Suqare, Park Lane, London W1K 6JP, United Kingdom. Speakers: J.P Errico, Chairman, founder, principal investor and CFO.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|